Repligen Corporation (NASDAQ:RGEN) Receives Consensus Rating of “Moderate Buy” from Analysts

Repligen Corporation (NASDAQ:RGEN) has been given an average rating of “Moderate Buy” by the fifteen analysts that are currently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, three have given a hold recommendation, ten have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $173.8462.

A number of research firms have commented on RGEN. Barclays raised their price target on shares of Repligen from $160.00 to $175.00 and gave the stock an “overweight” rating in a report on Wednesday, October 29th. Canaccord Genuity Group boosted their target price on shares of Repligen from $150.00 to $165.00 and gave the company a “hold” rating in a report on Wednesday, October 29th. Jefferies Financial Group set a $160.00 target price on Repligen and gave the stock a “hold” rating in a research report on Tuesday, October 28th. Wall Street Zen lowered Repligen from a “buy” rating to a “hold” rating in a research note on Tuesday, November 4th. Finally, HSBC initiated coverage on shares of Repligen in a report on Wednesday, October 1st. They set a “buy” rating and a $150.00 price target for the company.

Repligen Price Performance

Shares of NASDAQ RGEN opened at $165.02 on Wednesday. The company has a debt-to-equity ratio of 0.26, a current ratio of 8.59 and a quick ratio of 7.32. The stock has a market capitalization of $9.29 billion, a PE ratio of 8,255.13, a P/E/G ratio of 3.32 and a beta of 1.11. The business has a fifty day moving average price of $151.35 and a two-hundred day moving average price of $132.37. Repligen has a fifty-two week low of $102.96 and a fifty-two week high of $182.52.

Repligen (NASDAQ:RGEN) last posted its earnings results on Tuesday, October 28th. The biotechnology company reported $0.46 EPS for the quarter, topping analysts’ consensus estimates of $0.42 by $0.04. Repligen had a net margin of 0.25% and a return on equity of 4.70%. The firm had revenue of $188.81 million during the quarter, compared to analysts’ expectations of $181.23 million. During the same quarter in the prior year, the business earned $0.43 earnings per share. The business’s revenue for the quarter was up 21.9% compared to the same quarter last year. Repligen has set its FY 2025 guidance at 1.650-1.680 EPS. As a group, equities analysts predict that Repligen will post 1.72 earnings per share for the current fiscal year.

Insider Transactions at Repligen

In other news, Director Anthony Hunt sold 25,000 shares of the business’s stock in a transaction on Wednesday, November 12th. The stock was sold at an average price of $156.88, for a total value of $3,922,000.00. Following the completion of the transaction, the director owned 100,743 shares in the company, valued at $15,804,561.84. The trade was a 19.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, COO James Bylund sold 2,191 shares of the business’s stock in a transaction on Tuesday, November 18th. The shares were sold at an average price of $151.21, for a total transaction of $331,301.11. Following the sale, the chief operating officer owned 21,520 shares of the company’s stock, valued at approximately $3,254,039.20. This represents a 9.24% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 49,382 shares of company stock worth $7,676,802. 1.20% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Repligen

Several institutional investors have recently added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD grew its holdings in Repligen by 6.0% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 7,566,093 shares of the biotechnology company’s stock valued at $962,711,000 after purchasing an additional 430,039 shares during the last quarter. United Capital Financial Advisors LLC acquired a new stake in Repligen in the third quarter valued at approximately $368,387,000. Holocene Advisors LP grew its stake in shares of Repligen by 47.0% during the third quarter. Holocene Advisors LP now owns 1,377,104 shares of the biotechnology company’s stock worth $184,077,000 after acquiring an additional 440,290 shares during the last quarter. Alliancebernstein L.P. grew its holdings in shares of Repligen by 21.8% during the third quarter. Alliancebernstein L.P. now owns 1,104,171 shares of the biotechnology company’s stock valued at $147,595,000 after buying an additional 197,778 shares during the last quarter. Finally, Brown Capital Management LLC increased its stake in shares of Repligen by 16.3% in the second quarter. Brown Capital Management LLC now owns 1,005,276 shares of the biotechnology company’s stock worth $125,036,000 after acquiring an additional 141,241 shares during the period. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.